Comment on

• Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

  Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA 3rd, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team. Paredes R, et al. J Infect Dis. 2010 Mar;201(5):662-71. doi: 10.1086/650543. J Infect Dis. 2010. PMID: 20102271 Free PMC article.
• Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.

  Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D, Wantman M, Hammer SM, Palmer S, Vaida F, Coffin JM, Mellors JW. Halvas EK, et al. J Infect Dis. 2010 Mar;201(5):672-80. doi: 10.1086/650542. J Infect Dis. 2010. PMID: 20102272 Free PMC article.